Please login to the form below

Not currently logged in
Email:
Password:

Covance takes over abandoned Eli Lilly site

US pharmaceutical developer Covance buys Lilly's partially constructed facility to develop a Class A drug development laboratory

US pharmaceutical developer Covance has acquired Eli Lilly's partially constructed facility in the US state of Virginia to develop a Class A drug development laboratory.

Lilly began work on the USD 325m property for insulin manufacturing in 2006, but then abandoned construction halfway through in January 2007, citing changes in its global manufacturing strategy. The company returned approximately USD 5m in economic development incentives it received from the state to construct the 2.8-hectare site.

Covance will invest USD 175m in the project, which includes expanding the facility to about four hectares. It will relocate 450 employees to the property by 2011 from existing operations in Virginia and said it may hire an additional 100 employees by 2014.

Covance will also receive about USD 3.7m in state incentives.

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics